163 filings
Page 2 of 9
8-K
thbpalcrptl32q
4 Aug 22
Results of Operations and Financial Condition
7:01am
8-K
0cn0mf g87
27 Jun 22
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
4:12pm
8-K
6ex3nm6p
10 May 22
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights
7:07am
8-K
pjffai1prcnz3m6lx
10 Mar 22
Submission of Matters to a Vote of Security Holders
10:52am
8-K
9q1uylw4fntfmm
31 Mar 21
ESSA Announces Change to its Board of Directors
12:00am
8-K
7nfvxmlzc30q
2 Mar 21
Submission of Matters to a Vote of Security Holders
4:51pm
8-K
5gf7w0 99m9
22 Feb 21
Other Events
5:16pm
8-K
zi9wi
16 Feb 21
ESSA Pharma Provides Corporate Update and Reports Financial Results for Recent Clinical and Corporate Highlights
12:00am
8-K
j345j2rk04iayqx5x2c2
11 Feb 21
Other Events
10:28am
8-K
dxhd 6fdoe
15 Dec 20
ESSA Pharma Provides Corporate Update and Reports Financial Results for Clinical and Corporate Highlights for 2020 Fiscal Year
5:05pm
8-K
v12xp
27 Oct 20
ESSA Pharma Inc. Announces Delisting from the TSX-V
12:00am
6-K
vp3ip sac1sc
21 Sep 20
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
9:40am
6-K
er5lbd
17 Sep 20
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
5:22pm
6-K
22qypo32j60ugaj3
14 Sep 20
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
9:10am
6-K
5375vk7
10 Sep 20
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
9:10am
6-K
ex7t7io
7 Aug 20
Current report (foreign)
12:00am
6-K
fimktvf97kt
6 Aug 20
Current report (foreign)
12:19pm
6-K
2hlwfzvnbgt
31 Jul 20
Current report (foreign)
10:35am
6-K
457vi4n43
28 Jul 20
ESSA Pharma Announces Pricing of Public Offering of Common Shares
9:48pm
6-K
nhh7n6u1ekyn7b7
28 Jul 20
ESSA Pharma Announces Proposed Public Offering of Common Shares
4:24pm